Results 191 to 200 of about 95,214 (266)

High Expression of SSEA3 and Globo H Predicts Poor Outcomes in Resected Extrahepatic Cholangiocarcinoma: A Single‐Center Retrospective Cohort Study

open access: yesCancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background SSEA3, SSEA4, and Globo H glycosphingolipids have been implicated in tumor progression and immune modulation across various malignancies. However, their clinical significance in extrahepatic cholangiocarcinoma (eCCA) remains largely undefined.
Tsai‐Hsien Hung   +6 more
wiley   +1 more source

Open Cholecystectomy in a Patient With Situs Inversus Totalis and Symptomatic Cholelithiasis: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Situs inversus totalis (SIT) reverses normal anatomical landmarks used during cholecystectomy, requiring careful preoperative imaging, a mirror‐image surgical strategy, and strict achievement of the critical view of safety before ductal or vascular division.
Syeda Farwa Parihan Gillani   +5 more
wiley   +1 more source

Dieulafoy's Lesion of the Major Duodenal Papilla Presenting as Obscure Upper Gastrointestinal Bleeding: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Dieulafoy's lesion is an uncommon vascular anomaly that can cause life‐threatening gastrointestinal bleeding. While the stomach is the most frequently affected site, involvement of the major duodenal papilla is exceedingly rare and may escape detection with conventional forward‐viewing endoscopy.
Aref Arminfar   +5 more
wiley   +1 more source

Disulfiram‐Induced Hepatotoxicity in a Patient With Alcohol Use Disorder: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Disulfiram can cause severe and potentially fatal hepatotoxicity, particularly in patients with preexisting liver disease. In Bhutan, where alcohol‐related liver disease represents a major public health burden and pharmacological options for relapse prevention remain limited, careful patient selection, hepatic assessment, and early monitoring ...
Sonam Wangchuk   +2 more
wiley   +1 more source

Beyond Weight Loss: Tirzepatide as a Metabolic Disease‐Modifying Strategy for Metabolic Dysfunction‐Associated Steatohepatitis: A Narrative Review

open access: yesHealth Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and a major contributor to liver‐related morbidity and mortality. Its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), is characterized by hepatocellular injury, inflammation,
Zubaier Ahmed   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy